Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

1.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
[PubMed - indexed for MEDLINE]
2.

Triple negative tumours: a critical review.

Reis-Filho JS, Tutt AN.

Histopathology. 2008 Jan;52(1):108-18. doi: 10.1111/j.1365-2559.2007.02889.x. Review.

PMID:
18171422
[PubMed - indexed for MEDLINE]
3.

Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.

Diaz LK, Cryns VL, Symmans WF, Sneige N.

Adv Anat Pathol. 2007 Nov;14(6):419-30. Review.

PMID:
18049131
[PubMed - indexed for MEDLINE]
4.

Triple-negative breast cancer: therapeutic options.

Cleator S, Heller W, Coombes RC.

Lancet Oncol. 2007 Mar;8(3):235-44. Review.

PMID:
17329194
[PubMed - indexed for MEDLINE]
5.

Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?

Burness ML, Grushko TA, Olopade OI.

Cancer J. 2010 Jan-Feb;16(1):23-32. doi: 10.1097/PPO.0b013e3181d24fc1. Review.

PMID:
20164687
[PubMed - indexed for MEDLINE]
6.

The molecular pathology of hereditary breast cancer.

Palacios J, Robles-Frías MJ, Castilla MA, López-García MA, Benítez J.

Pathobiology. 2008;75(2):85-94. doi: 10.1159/000123846. Epub 2008 Jun 10. Review.

PMID:
18544963
[PubMed - indexed for MEDLINE]
7.

The basal phenotype of BRCA1-related breast cancer: past, present and future.

Tischkowitz MD, Foulkes WD.

Cell Cycle. 2006 May;5(9):963-7. Epub 2006 May 1. Review.

PMID:
16687925
[PubMed - indexed for MEDLINE]
Free Article
8.

Triple-negative breast cancer: an unmet medical need.

Hudis CA, Gianni L.

Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01. Review.

PMID:
21278435
[PubMed - indexed for MEDLINE]
Free Article
9.

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

Jaspers JE, Rottenberg S, Jonkers J.

Biochim Biophys Acta. 2009 Dec;1796(2):266-80. doi: 10.1016/j.bbcan.2009.07.001. Epub 2009 Jul 17. Review.

PMID:
19616605
[PubMed - indexed for MEDLINE]
Free Article
10.

The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.

Honrado E, Benítez J, Palacios J.

Mod Pathol. 2005 Oct;18(10):1305-20. Review.

PMID:
15933754
[PubMed - indexed for MEDLINE]
Free Article
11.

Triple negative breast cancers: clinical and prognostic implications.

Dawson SJ, Provenzano E, Caldas C.

Eur J Cancer. 2009 Sep;45 Suppl 1:27-40. doi: 10.1016/S0959-8049(09)70013-9. Review.

PMID:
19775602
[PubMed - indexed for MEDLINE]
12.

Triple-negative breast cancer: disease entity or title of convenience?

Carey L, Winer E, Viale G, Cameron D, Gianni L.

Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28. Review.

PMID:
20877296
[PubMed - indexed for MEDLINE]
13.

Triple negative breast carcinomas: similarities and differences with basal like carcinomas.

Lerma E, Barnadas A, Prat J.

Appl Immunohistochem Mol Morphol. 2009 Dec;17(6):483-94. doi: 10.1097/PAI.0b013e3181a725eb. Review.

PMID:
19620842
[PubMed - indexed for MEDLINE]
14.

Triple-negative breast cancer: current state of the art.

Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S.

Tumori. 2010 Nov-Dec;96(6):875-88. Review.

PMID:
21388048
[PubMed - indexed for MEDLINE]
15.

Triple negative breast cancer: from molecular portrait to therapeutic intervention.

Carotenuto P, Roma C, Rachiglio AM, Botti G, D'Alessio A, Normanno N.

Crit Rev Eukaryot Gene Expr. 2010;20(1):17-34. Review.

PMID:
20528735
[PubMed - indexed for MEDLINE]
16.

"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.

Nanda R.

Semin Oncol. 2011 Apr;38(2):254-62. doi: 10.1053/j.seminoncol.2011.01.007. Review.

PMID:
21421115
[PubMed - indexed for MEDLINE]
17.

[Triple-negative breast carcinoma--rewiev of current literature].

Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M.

Magy Onkol. 2010 Dec;54(4):325-35. doi: 10.1556/MOnkol.54.2010.4.6. Review. Hungarian.

PMID:
21163763
[PubMed - indexed for MEDLINE]
Free Article
18.

BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.

Santarosa M, Maestro R.

Cancer Metastasis Rev. 2012 Jun;31(1-2):131-42. doi: 10.1007/s10555-011-9336-6. Review.

PMID:
22101651
[PubMed - indexed for MEDLINE]
19.

Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.

Venkitaraman R.

Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207. doi: 10.1586/era.09.189. Review.

PMID:
20131996
[PubMed - indexed for MEDLINE]
20.

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Anders CK, Carey LA.

Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81. doi: 10.3816/CBC.2009.s.008. Review.

PMID:
19596646
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk